OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
Location: United States, California, Palo Alto
Employees: 1-10
Total raised: $129.3M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 09.11.2023 | Longitude ... | longitudec... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 09.09.2024 | Series B | $67M | - |
| 07.11.2023 | Series A | $60M | - |
| 02.11.2022 | Grant | $2.3M | - |
Mentions in press and media 4
| Date | Title | Description |
| 09.09.2024 | OrsoBio Raises $67M in Series B Financing | OrsoBio, Inc., a Menlo Park, CA-based clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, closed a $67m Series B financing. The round was co-led by new investors Ascenta Capital and W... |
| 06.09.2024 | OrsoBio: $67 Million (Series B) Secured To Develop Treatments For Obesity | OrsoBio – a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders – announced the closing of an oversubscribed $67 million Series B financing. The funding was co-led by new investors Asc... |
| 07.11.2023 | OrsoBio Raises $60M Series A Financing | OrsoBio, a Menlo Park, CA-based clinical-stage biopharmaceutical company, raised $60M in Series A funding. The round, which brought the toal amount to $97M, was led by Longitude Capital and Enavate Sciences. Existing investors Samsara BioCa... |
| - | OrsoBio | “Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, severe dyslipidemias, and more.” |